Financials in USD. Standardized financial statements.
A compact view of how 2seventy bio, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue? | $37.86M | $100.39M | $91.50M | $54.52M | $248.12M | $44.30M | $54.58M |
| Revenue Growth? | -62.3% | +9.7% | +67.8% | -78.0% | +460.1% | -18.8% | 0.0% |
| Cost of Revenue? | $22.56M | $16.92M | $26.22M | $12.59M | $5.40M | $2.98M | $885,000 |
| Gross Profit? | $15.30M | $83.47M | $65.28M | $41.93M | $242.73M | $41.32M | $53.69M |
| Gross Margin? | +40.4% | +83.1% | +71.3% | +76.9% | +97.8% | +93.3% | +98.4% |
| Operating Expenses? | $130.73M | $321.08M | $328.19M | $355.44M | $387.36M | $379.29M | $254.12M |
| Operating Income? | -$115.43M | -$237.61M | -$262.91M | -$313.51M | -$144.64M | -$337.97M | -$203.43M |
| EBITDA? | -$98.45M | -$206.42M | -$251.38M | -$297.16M | -$131.45M | -$325.39M | -$187.08M |
| Income Before Tax | -$57.25M | -$217.57M | -$254.15M | -$292.21M | -$120.11M | -$320.59M | -$199.75M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$57.25M | -$217.57M | -$254.14M | -$276.21M | -$138.17M | -$323.34M | -$199.75M |
| EPS? | $-1.10 | $-4.42 | $-7.13 | $-11.71 | $-5.93 | $-13.88 | $-8.58 |
| Diluted EPS? | $-1.10 | $-4.42 | $-7.13 | $-11.71 | $-5.93 | $-13.88 | $-8.58 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality